These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8031338)

  • 41. Nasty side-effects anticipated.
    Edwards N
    Health Serv J; 2011 Feb; 121(6245):16-7. PubMed ID: 21688425
    [No Abstract]   [Full Text] [Related]  

  • 42. The NHS drug budget inquiry. A note for the Commons Health Select Committee.
    Herxheimer A
    J R Coll Physicians Lond; 1994; 28(3):261-3. PubMed ID: 7932326
    [No Abstract]   [Full Text] [Related]  

  • 43. Reflections on a month in the life of the Ontario Drug Benefit Plan.
    McIsaac W; Naylor CD; Anderson GM; O'Brien BJ
    CMAJ; 1994 Feb; 150(4):473-7. PubMed ID: 8313259
    [No Abstract]   [Full Text] [Related]  

  • 44. [Dr Knock's return in reality: "Everyone is sick--but not everyone is aware about that!"].
    Melander A; Järhult B; Lindahl SO
    Lakartidningen; 2004 Jun; 101(23):2031. PubMed ID: 15232844
    [No Abstract]   [Full Text] [Related]  

  • 45. Experts get snagged on health's thorniest issue.
    Crump H
    Health Serv J; 2008 Sep; ():12-3. PubMed ID: 18810837
    [No Abstract]   [Full Text] [Related]  

  • 46. Paying the pharmacist under the British National Health Service.
    Smith MC; Booth TG; Jones I
    Inquiry; 1973 Sep; 10(3):57-64. PubMed ID: 4269731
    [No Abstract]   [Full Text] [Related]  

  • 47. Prescribing analysis and cost tabulation (PACT) data: an introduction.
    Lovejoy AE; Savage I
    Br J Community Nurs; 2001 Feb; 6(2):62-7. PubMed ID: 11927873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I.
    Carley DW
    IDrugs; 2005 Apr; 8(4):306-9. PubMed ID: 15800804
    [No Abstract]   [Full Text] [Related]  

  • 49. The costs of making practice more cost-effective.
    Weeks WB; Wallace AE
    JAMA; 2002 Apr; 287(13):1648; author reply 1649-50. PubMed ID: 11926883
    [No Abstract]   [Full Text] [Related]  

  • 50. [The national health authority and the responsibility for cost-effective drug utilization].
    Meland E; Wapler P
    Tidsskr Nor Laegeforen; 2001 Jun; 121(17):2094-5. PubMed ID: 11875912
    [No Abstract]   [Full Text] [Related]  

  • 51. Who knows the cost of antibiotics?
    Leigh DA
    J Antimicrob Chemother; 1981 Jun; 7(6):589-90. PubMed ID: 7251528
    [No Abstract]   [Full Text] [Related]  

  • 52. Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before?
    Taylor D; Craig T
    Health Econ Policy Law; 2009 Oct; 4(Pt 4):515-26. PubMed ID: 19715634
    [No Abstract]   [Full Text] [Related]  

  • 53. Regulating the pharmaceutical industry. Authors seem to have misunderstood pharmaceutical price regulation scheme.
    Read P
    BMJ; 1998 Jan; 316(7126):226; author reply 228. PubMed ID: 9468700
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic conservatism.
    Walley T
    J R Coll Physicians Lond; 1993 Jul; 27(3):337-8. PubMed ID: 8377174
    [No Abstract]   [Full Text] [Related]  

  • 55. [Induced drug prescription in oncology patients].
    Mas Arcas C; Pascual Plá F; Escrivá Muñz JJ; Boscas Mayans R
    Farm Hosp; 2004; 28(2):97-100. PubMed ID: 15101800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical Cost Savings in the Intensive Care Unit.
    Pennell BT; Murphy CV; Byrd C; Tubbs C
    Crit Care Nurs Q; 2017; 40(4):414-423. PubMed ID: 28834862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmaceutical starter samples.
    Teichman PG; Caffee AE
    J Am Board Fam Pract; 2002; 15(6):509-10. PubMed ID: 12463302
    [No Abstract]   [Full Text] [Related]  

  • 58. Free drugs for all?
    Maynard A
    J R Soc Med; 2009 May; 102(5):170-1. PubMed ID: 19417045
    [No Abstract]   [Full Text] [Related]  

  • 59. An analysis of specialty costs in an NHS region.
    Ferster G; Butts M
    Hosp Health Serv Rev; 1977 Nov; 73(11):390-3. PubMed ID: 10304559
    [No Abstract]   [Full Text] [Related]  

  • 60. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.